Lupus Nephritis: Navigating Therapeutic Possibilities to Optimize Outcomes This activity is supported by an educational grant from Genentech, a member of the Roche Group.

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...

FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis By Lori Solomon HealthDay ReporterMONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug ...

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with ...

Lupus nephritis articles from across Nature Portfolio Lupus nephritis is an inflammatory kidney disease (glomerulonephritis) that develops in patients with systemic lupus erythematosus (SLE).

The authors study how apolipoprotein L1 variants impact inflammation and lipid accumulation in macrophages. The findings will be useful for researchers investigating macrophage metabolism and ...